We are live on ! Find out more
CLVS

Clovis Oncology, Inc.

Delisted

CLVS was delisted on the 20th of December, 2022.

137 hedge funds and large institutions have $1.87B invested in Clovis Oncology, Inc. in 2014 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 64 increasing their positions, 25 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 10

156% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 25

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

36% more call options, than puts

Call options by funds: $31.7M | Put options by funds: $23.3M

23% more capital invested

Capital invested by funds: $1.52B → $1.87B (+$356M)

22% more funds holding

Funds holding: 112137 (+25)

Holders
137
Holders Change
+25
Holders Change %
+22.32%
% of All Funds
3.96%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
36
Increased
64
Reduced
25
Closed
10
Calls
$31.7M
Puts
$23.3M
Net Calls
+$8.39M
Net Calls Change
+$13.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Citigroup
101
Citigroup
New York
$573K -$192K -2,614 -24%
Prudential Financial
102
Prudential Financial
New Jersey
$532K +$491K +6,680 New
California Public Employees Retirement System
103
California Public Employees Retirement System
California
$528K +$593K +8,071 New
UBS AM
104
UBS AM
Illinois
$520K +$29.4K +400 +6%
TAM
105
Tocqueville Asset Management
New York
$478K +$206K +2,800 +68%
Barclays
106
Barclays
United Kingdom
$447K -$312K -4,255 -40%
SCM
107
Stevens Capital Management
Pennsylvania
$425K +$450K +6,134 New
HI
108
HBK Investments
Texas
$423K -$1.95M -26,600 -81%
III
109
Independent Investors Inc
New York
$415K
DCM
110
Dupont Capital Management
Delaware
$400K
QIM
111
Quantitative Investment Management
Virginia
$374K +$125K +1,700 +46%
PAM
112
Paradigm Asset Management
New York
$371K
GLRA
113
Gerald L. Ray & Associates
Texas
$346K +$51.4K +700 +16%
Capital Fund Management (CFM)
114
Capital Fund Management (CFM)
France
$288K +$305K +4,154 New
ST
115
Spot Trading
Illinois
$224K +$237K +3,233 New
PNC Financial Services Group
116
PNC Financial Services Group
Pennsylvania
$208K +$221K +3,011 New
Dimensional Fund Advisors
117
Dimensional Fund Advisors
Texas
$171K +$179K +2,443 New
RNS
118
Robert N. Shapiro
$162K
Credit Agricole
119
Credit Agricole
France
$159K +$169K +2,300 New
PG
120
PEAK6 Group
Illinois
$121K +$129K +1,750 New
PAM
121
Panagora Asset Management
Massachusetts
$94K +$100K +1,364 New
TRCT
122
Tower Research Capital (TRC)
New York
$90K +$47.7K +650 +99%
MAA
123
Managed Account Advisors
New Jersey
$71K +$74.8K +1,019 New
NSIM
124
North Star Investment Management
Illinois
$69K +$73.4K +1,000 New
ClearBridge Investments
125
ClearBridge Investments
New York
$58K +$31K +422 +103%

CLVS Hedge Fund Activity: Q1 2014 in Review

137 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2014, worth a combined $1.87B — up 23% from $1.52B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new CLVS positions and 10 closed out — a net gain of 26 holders — while 64 added to existing stakes and 25 trimmed.

The largest buyer was OppenheimerFunds, opening a new position worth an estimated $62.5M. The largest seller was PFM Health Sciences, cutting an estimated $111M.

  • 137 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2014, up from 112 in Q4 2013.
  • Funds reported $1.87B of Clovis Oncology, Inc. stock for Q1 2014, up 23% quarter-over-quarter.
  • 36 funds opened new Clovis Oncology, Inc. positions in Q1 2014 and 10 closed out, a net change of +26 holders.
  • The largest Clovis Oncology, Inc. buyer in Q1 2014 was OppenheimerFunds, an estimated $62.5M added.
  • The largest Clovis Oncology, Inc. seller in Q1 2014 was PFM Health Sciences, an estimated $111M sold.

Based on aggregated 13F filings for Q1 2014.